A disciplined, highly targeted approach to discovering new cancer medicines
Rigorous, definitive clinical trials based on deep oncology expertise
Committed to bringing differentiated new cancer medicines to patients
ARIAD's first internally discovered and developed medicine
ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma
ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results
A shared commitment to patients and each other. This is ARIAD.